Patents by Inventor Iwona Wrona

Iwona Wrona has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210139471
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 13, 2021
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • Patent number: 10919885
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: February 16, 2021
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Iwona Wrona, Parcharee Tivitmahaisoon, Daniel Tardiff, Bhaumik Pandya, Kerem Ozboya, Matthew Lucas, Bertrand Le Bourdonnec
  • Publication number: 20200262828
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 20, 2020
    Inventors: Matthew LUCAS, Bertrand LE BOURDONNEC, Iwona WRONA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Kerem OZBOYA, Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Kenneth RHODES
  • Publication number: 20200010462
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: October 24, 2017
    Publication date: January 9, 2020
    Inventors: Matthew LUCAS, Bertrand LE BOURDONNEC, Iwona WRONA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Kerem OZBOYA, Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Kenneth Rhodes
  • Publication number: 20190330198
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 31, 2019
    Inventors: Iwona WRONA, Parcharee TIVITMAHAISOON, Daniel TARDIFF, Bhaumik PANDYA, Kerem OZBOYA, Matthew LUCAS, Bertrand Le BOURDONNEC
  • Patent number: 10428072
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 1, 2019
    Assignee: Eli Lilly and Company
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • Publication number: 20180230149
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: March 29, 2018
    Publication date: August 16, 2018
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • Publication number: 20170050966
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: April 23, 2015
    Publication date: February 23, 2017
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher Matthew Liu, Guohua Liang, Matthew F. Baevsky, Richard Alan Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans